Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Status:
Terminated
Trial end date:
2018-10-09
Target enrollment:
Participant gender:
Summary
This study uses a drug called dasatinib to produce an anti-cancer effect called large
granular lymphocyte cellular expansion. Large granular lymphocytes are blood cells known as
natural killer cells that remove cancer cells. Researchers think that dasatinib may cause
large granular lymphocyte expansion to happen in patients who have received a blood stem cell
transplant (SCT) between 3 to 15 months after the SCT. In this research study, researchers
want to find how well dasatinib can be tolerated, the best dose to take of dasatinib and how
to estimate how often large granular lymphocytic cellular expansion happens at the best dose
of dasatinib.